Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2021 – Wrap-Up
SABCS 2021 – Wrap-Up
Wrap-Up
Finding Your Strength Through Knowledge: Proceedings from the San Antonio Breast Cancer Symposium
SABCS 2021 – Wrap-Up
Several novel breast cancer therapies have come onto the market in recent years, significantly changing the breast cancer landscape, specifically in the metastatic setting. The Pathways Heart Study has looked at cardiovascular outcomes and risk variables from breast cancer treatments. A number of breast cancer risk factors as well as the benefits of physical exercise and aspirin use among breast cancer survivors are discussed in this review.
Read More ›
Wrap-Up
Updated Outcomes of Tucatinib versus Placebo Added to Trastuzumab and Capecitabine (HER2CLIMB) in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer with Brain Metastases
SABCS 2021 – Wrap-Up
Tucatinib added to trastuzumab and capecitabine resulted in a substantial and permanent improvement of progression-free survival and overall survival for all patients with
HER2
-positive metastatic breast cancer with brain metastases, as confirmed by results from the HER2CLIMB study.
Read More ›
Videos
Wrap-Up
Finding Your Strength Through Knowledge
By
Sharon Gentry, RN, MSN, AOCN, CBCN, HON-ONN-CG
SABCS 2021 – Wrap-Up
Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, shares topics presented at the 2021 San Antonio Breast Cancer Symposium to help empower patients with breast cancer.
Read More ›
Wrap-Up
Results from the I-SPY 2 Trial of Tucatinib plus Paclitaxel + Pertuzumab + Trastuzumab Followed by Doxorubicin/Cyclophosphamide in High-Risk HER2-Positive Stage II/III Breast Cancer
SABCS 2021 – Wrap-Up
Tucatinib-containing therapy resulted in a tumor volume reduction of >80%. Tucatinib was found to be highly effective when combined with paclitaxel plus trastuzumab plus pertuzumab.
Read More ›
Wrap-Up
A Review of the Efficacy of Tyrosine Kinase Inhibitors in the Treatment of Patients with HER2-Positive Breast Cancer with or without Brain Metastases
SABCS 2021 – Wrap-Up
Tyrosine kinase inhibitor (TKI) treatments show equal overall survival and progression-free survival (PFS) benefits in patients with
HER2
-positive breast cancer with and without brain metastases.
Read More ›
Wrap-Up
Intracranial Efficacy of Tucatinib, Palbociclib, and Letrozole in Patients with Hormone Receptor–Positive, HER2-Positive Breast Cancer with Brain Metastases
SABCS 2021 – Wrap-Up
The combination regimen of tucatinib, palbociclib, and letrozole in patients with hormone receptor–positive,
HER2
-positive breast cancer with brain metastases demonstrates an improved central nervous system progression-free survival in a small group of patients.
Read More ›
Wrap-Up
Safety and Efficacy of a Tucatinib-Trastuzumab-Capecitabine Combination Treatment for Leptomeningeal Metastases in HER2-Positive Breast Cancer
SABCS 2021 – Wrap-Up
Tucatinib-trastuzumab-capecitabine combination therapy has been shown to double the overall survival in patients with
HER2
-positive breast cancer with leptomeningeal metastases.
Read More ›
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us